Drug Profile
Research programme: cancer therapeutics - BioPatterns
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator BioPatterns
- Class Antineoplastics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Sep 2023 Preclinical development is ongoing in Czech Republic (BioPatterns website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in Czech Republic
- 04 Aug 2016 Research programme: cancer therapeutics - BioPatterns is available for licensing as of 04 Aug 2016. http://www.biopatterns.cz/